Avidity Biosciences Announces Record Date for Spin-Off to Novartis.
ByAinvest
Tuesday, Feb 3, 2026 5:31 pm ET1min read
NVS--
RNA--
Avidity Biosciences has designated February 12, 2026 as the record date for the pro rata distribution of Atrium Therapeutics shares to holders of Avidity common stock. This comes as part of the proposed acquisition of Avidity by Novartis AG and the separation of Avidity's early-stage precision medicine assets into a standalone company. The spin-off is expected to create a new biopharmaceutical company focused on developing RNA therapeutics.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet